Goldman Sachs analyst Kevin Strang initiates coverage on Stoke Therapeutics (NASDAQ: STOK) with a Buy rating and a price target ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments New Coverage